215 related articles for article (PubMed ID: 30592080)
1. Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Hamlin PA; Flinn IW; Wagner-Johnston N; Burger JA; Coffey GP; Conley PB; Michelson G; Leeds JM; Der K; Kim Y; Sabalvaro-Torres A; Birrell M; Pandey A; Curnutte JT; Patel MR
Am J Hematol; 2019 Apr; 94(4):E90-E93. PubMed ID: 30592080
[No Abstract] [Full Text] [Related]
2. Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
Coffey GP; Feng J; Betz A; Pandey A; Birrell M; Leeds JM; Der K; Kadri S; Lu P; Segal J; Wang YL; Michelson G; Curnutte JT; Conley PB
Clin Cancer Res; 2019 Feb; 25(4):1174-1184. PubMed ID: 30333224
[TBL] [Abstract][Full Text] [Related]
3. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Ishikawa C; Senba M; Mori N
Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853
[TBL] [Abstract][Full Text] [Related]
4. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
5. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
[TBL] [Abstract][Full Text] [Related]
6. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
[TBL] [Abstract][Full Text] [Related]
7. Syk inhibitors in clinical development for hematological malignancies.
Liu D; Mamorska-Dyga A
J Hematol Oncol; 2017 Jul; 10(1):145. PubMed ID: 28754125
[TBL] [Abstract][Full Text] [Related]
8. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis.
Piscitelli SC; Pavel AB; McHale K; Jett JE; Collins J; Gillmor D; Tabolt G; Li R; Song T; Zhang N; Tallman AM; Guttman-Yassky E
J Invest Dermatol; 2021 Jul; 141(7):1847-1851. PubMed ID: 33493530
[No Abstract] [Full Text] [Related]
10. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M; Santoro A; Mollica L; Leppä S; Follows GA; Lenz G; Kim WS; Nagler A; Panayiotidis P; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Giurescu M; Cupit L; Liu L; Köchert K; Seidel H; Peña C; Yin S; Hiemeyer F; Garcia-Vargas J; Childs BH; Zinzani PL
J Clin Oncol; 2017 Dec; 35(35):3898-3905. PubMed ID: 28976790
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
[No Abstract] [Full Text] [Related]
12. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
13. Final results of a phase 1b study of the safety and efficacy of the PI3Kδ inhibitor acalisib (GS-9820) in relapsed/refractory lymphoid malignancies.
Kater AP; Tonino SH; Spiering M; Chamuleau MED; Liu R; Adewoye AH; Gao J; Dreiling L; Xin Y; Doorduijn JK; Kersten MJ;
Blood Cancer J; 2018 Feb; 8(2):16. PubMed ID: 29434192
[No Abstract] [Full Text] [Related]
14. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
15. A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease.
Kheirkhah A; Di Zazzo A; Satitpitakul V; Fernandez M; Magilavy D; Dana R
Cornea; 2017 Jul; 36(7):799-804. PubMed ID: 28445193
[TBL] [Abstract][Full Text] [Related]
16. Initial treatment of B-cell prolymphocytic leukemia with ibrutinib.
Moore J; Baran AM; Meacham PJ; Evans AG; Barr PM; Zent CS
Am J Hematol; 2020 May; 95(5):E108-E110. PubMed ID: 31951033
[No Abstract] [Full Text] [Related]
17. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
18. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
[TBL] [Abstract][Full Text] [Related]
19. Changes in serum diamine oxidase activity during chemotherapy in patients with hematological malignancies.
Tsujikawa T; Uda K; Ihara T; Inoue T; Andoh A; Fujiyama Y; Bamba T
Cancer Lett; 1999 Dec; 147(1-2):195-8. PubMed ID: 10660106
[TBL] [Abstract][Full Text] [Related]
20. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Yazici Y; Regens AL
Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
